Wiktoria Mazepa

Wiktoria Mazepa

Auto-generated profile, based on publicly available information

Wiktoria Mazepa

Medical University of Warsaw, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
SOSara Zahra Omidi
Sara Zahra Omidi
DKDaria Valipur Kolti
Daria Valipur Kolti
JKJerzy Klimas
Jerzy Klimas
BOBarbara Olędzka
Barbara Olędzka
WMWiktoria Mazepa
Wiktoria Mazepa
ZRZofia Rogowska
Zofia Rogowska
Anifrolumab is a fully human IgG1 monoclonal antibody targeting the IFNAR1 subunit of the type I interferon receptor. By inhibiting the JAK-STAT signaling pathway and suppressing interferon-stimulated gene expression, anifrolumab represents a targeted therapy based on disease pathophysiology. The drug has been approved as an add-on treatment for adult patients with moderate to severe systemic lupus erythematosus particularly in patients in whom standard therapies such as systemic glucocorticoids and hydroxychloroquine have failed to achieve the desired outcomes. The efficacy of anifrolumab has been assessed in several randomized clinical trials, which demonstrated a significant reduction in disease activity, decreased rates of disease flares, and improvement in cutaneous and musculoskeletal manifestations. Another clinically relevant outcome was the possibility to reduce glucocorticosteroid doses. Further analyses also suggest a beneficial effect of anifrolumab in lupus nephritis and indicate its superiority over standard therapy. Anifrolumab has demonstrated a favorable safety profile, with no significant increase in the risk of serious adverse events or opportunistic infections. The most frequently reported adverse events were upper respiratory tract infections as well as varicella and herpes zoster infections. In Poland, anifrolumab is registered exclusively for the treatment of adults with moderate to severe systemic lupus erythematosus as an adjunct to standard therapy. However, evidence from clinical trials and case series suggest the potential for broader application of this drug in dermatology in the coming years. In the future, anifrolumab may also be considered a therapeutic option in refractory cases of cutaneous lupus erythematosus.

19 August 2026 in Medical Science Pulse
Verified
Journal Article
Closed access
BOBarbara Olędzka
Barbara Olędzka
MPMichał Piątkiewicz
Michał Piątkiewicz
MOMałgorzata OlęDzka
Małgorzata OlęDzka
WMWiktoria Mazepa
Wiktoria Mazepa
SOSara Zahra Omidi
Sara Zahra Omidi
EKElżbieta Kowalska-OlęDzka
Elżbieta Kowalska-OlęDzka
Background: Lupus erythematosus is a chronic multisystem autoimmune disease affecting both internal organs and the skin. It may present as a skin-limited condition, referred to as cutaneous lupus erythematosus, or as a potentially life-threatening systemic disorder, systemic lupus erythematosus. Skin involvement is observed in up to 80% of patients with systemic lupus erythematosus, and cutaneous disease represents the initial manifestation of the systemic form in approximately 25% of cases. Despite this substantial burden, knowledge of the disease among physicians and nurses remains inconsistent, and hospitalization affects roughly 10% of patients annually, underscoring the need for a consolidated, multidisciplinary summary of current management.Aim of the study: The aim of this study was to synthesize current clinical knowledge regarding lupus erythematosus, outline diagnostic and therapeutic strategies, and emphasize the critical role of multidisciplinary care, patient education, and addressing the psychological burden associated with the disease.Materials and methods: A narrative review was conducted through a comprehensive literature search across PubMed, Scopus, and Web of Science (between 17 February and 29 March 2026). A total of 50 publications were included, comprising clinical practice guidelines, systematic reviews and meta-analyses, randomized controlled trials, and original clinical studies, including the EULAR/ACR criteria.Results: Lupus diagnosis relies primarily on the 2019 EULAR/ACR criteria. The cornerstone of treatment comprises antimalarial drugs, supported by immunosuppression and biological therapies. Non-pharmacological management remains crucial, particularly strict photoprotection and complete smoking cessation. The multisystem nature of the disease requires care coordinated by a rheumatologist in close collaboration with a cardiologist, nephrologist, dermatologist, and other specialists. The patients' psychological burden, including depression, necessitates psychiatric support and modern educational tools, which directly improve treatment adherence, a pressing concern, as non-adherence affects up to 62% of patients with SLE, with depression and polypharmacy independently increasing the risk.Conclusions: Effective management of lupus extends beyond pharmacology alone. Clinical success requires close cooperation within a multidisciplinary team, integrated psychological support, and ongoing patient education, which collectively help prevent relapses and enhance overall quality of life.